{
  "id": 252840,
  "title": "Personalized Neoantigen Vaccines Synergize with Immune Checkpoint Therapy and CD8-Targeted Cytokines to Control B-Cell Lymphoma",
  "url": "https://urgent.news/2026/08/06/personalized-neoantigen-vaccines-synergize-with-immune-checkpoint",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-06T00:00:00.000Z",
  "source": {
    "name": "bioRxiv",
    "slug": "biorxiv",
    "url": "https://www.biorxiv.org/content/10.64898/2026.08.02.742304v1?rss=1"
  },
  "original_language": "en",
  "account": "A personalized neoantigen vaccine has proven effective when combined with immune checkpoint therapy and CD8-targeted cytokines, specifically in the treatment of B-cell lymphoma. Initially, subcutaneous A20 tumors were resistant to single-agent anti-PD-1 or anti-CTLA4 therapy; however, dual immune checkpoint therapy yielded a 90% eradication rate in T cell-dependent manner. By identifying dominant endogenous A20 MHC-I and MHC-II neoantigens, researchers created a therapeutic synthetic long peptide (SLP) vaccine.\n\nThis A20 neoVAX vaccine stimulated robust neoantigen-specific CD4 and CD8 T cell responses in mice, leading to tumor rejection in approximately 70% of cases. When tested in an immunocompetent syngeneic A20 B-cell lymphoma platform, dual immune checkpoint therapy was initially ineffective. However, A20 neoVAX combined with anti-PD-1 delayed tumor progression and prolonged animal survival. The combination of A20 neoVAX plus dual immune checkpoint therapy achieved durable systemic tumor elimination.\n\nTo minimize potential adverse events, genetically modified CD8-targeted cytokine muteins (CD8-IL2 or CD8-IL21) were used in place of anti-CTLA4. When A20 neoVAX was combined with CD8-IL2 or CD8-IL21 and anti-PD-1, 66.7% of tumor-bearing mice successfully rejected their lymphoma. Similarly, when CD8-IL21 replaced CD8-IL2, tumor clearance was observed in two-thirds of A20-bearing mice, without the need for anti-PD-1. These findings provide a framework for optimal personalized neoantigen vaccination in B-lymphoma, demonstrating that neoantigen vaccines can safely synergize with CD8+ T cell-selective immunotherapies to prevent T-cell dysfunction and generate durable systemic anti-tumor immunity.",
  "summary": "Personalized neoantigen (neoAg) vaccines have shown clinical promise in solid tumors1-8, yet their efficacy and mechanism of action in hematopoietic malignancies remain poorly defined9-11. Herein, we establish an immunocompetent syngeneic A20 B-cell lymphoma platform to test the efficacy of neoAg vaccines used either as mono- or combinatorial therapies with other immunotherapies12-17. Whereas…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}